🇺🇸 FDA
Pipeline program

A research study comparing different ways of increasing the dose of NNC0519-0130 in participants with overweight or obesity

NN9541-7760

Phase 1 other active

Quick answer

A research study comparing different ways of increasing the dose of NNC0519-0130 in participants with overweight or obesity for Type 2 diabetes mellitus is a Phase 1 program (other) at Novo Nordisk A/S with 1 ClinicalTrials.gov record(s).

Program details

Company
Novo Nordisk A/S
Indication
Type 2 diabetes mellitus
Phase
Phase 1
Modality
other
Status
active

Clinical trials